Sonnet BioTherapeuticsSONN
SONN
About: Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Employees: 13
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
4,287% more capital invested
Capital invested by funds: $2.97K [Q3] → $130K (+$127K) [Q4]
350% more funds holding
Funds holding: 2 [Q3] → 9 (+7) [Q4]
2.95% more ownership
Funds ownership: 0.01% [Q3] → 2.96% (+2.95%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
1,393%
upside
Avg. target
$20
1,393%
upside
High target
$20
1,393%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Keay Nakae 14% 1-year accuracy 10 / 69 met price target | 1,393%upside $20 | Buy Maintained | 20 Dec 2024 |
Financial journalist opinion
Based on 6 articles about SONN published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here
Neutral
GlobeNewsWire
2 weeks ago
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ® ) provides enhanced targeting to the tumor microenvironment (TME) and prolonged retention in the tumor PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the presentation of a compilation of data at the 2025 American Association for Cancer Research (AACR) IO Conference.
Neutral
GlobeNewsWire
3 weeks ago
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)
Neutral
GlobeNewsWire
3 weeks ago
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its abstract has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference taking place on February 23-26, 2025 at the JW Marriott in Los Angeles, CA.
Neutral
GlobeNewsWire
4 weeks ago
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025.
Neutral
GlobeNewsWire
4 weeks ago
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR)
Neutral
GlobeNewsWire
1 month ago
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins
Neutral
GlobeNewsWire
1 month ago
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Live webcast on Wednesday, January 29 th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that Pankaj Mohan, Ph.D., Chief Executive Officer of Sonnet will present at LIVE!
Neutral
GlobeNewsWire
1 month ago
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis ® ) with the potential to improve trabectedin's therapeutic window in soft-tissue sarcoma patients
Neutral
GlobeNewsWire
2 months ago
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company's website .
Charts implemented using Lightweight Charts™